de Faria Stephanie Martins, de Morais Fabrício Daiene, Tumas Vitor, Castro Paula Costa, Ponti Moacir Antonelli, Hallak Jaime Ec, Zuardi Antonio W, Crippa José Alexandre S, Chagas Marcos Hortes Nisihara
Department of Gerontology, Federal University of São Carlos, São Carlos, Brazil.
Department of Psychology, Federal University of São Carlos, São Carlos, Brazil.
J Psychopharmacol. 2020 Feb;34(2):189-196. doi: 10.1177/0269881119895536. Epub 2020 Jan 7.
Cannabidiol (CBD) is one of the main components of and has anxiolytic properties, but no study has been conducted to evaluate the effects of CBD on anxiety signs and symptoms in patients with Parkinson's disease (PD). This study aimed to evaluate the impacts of acute CBD administration at a dose of 300 mg on anxiety measures and tremors induced by a Simulated Public Speaking Test (SPST) in individuals with PD.
A randomised, double-blinded, placebo-controlled, crossover clinical trial was conducted. A total of 24 individuals with PD were included and underwent two experimental sessions within a 15-day interval. After taking CBD or a placebo, participants underwent the SPST. During the test, the following data were collected: heart rate, systemic blood pressure and tremor frequency and amplitude. In addition, the Visual Analog Mood Scales (VAMS) and Self-Statements during Public Speaking Scale were applied. Statistical analysis was performed by repeated-measures analysis of variance (ANOVA) while considering the drug, SPST phase and interactions between these variables.
There were statistically significant differences in the VAMS anxiety factor for the drug; CBD attenuated the anxiety experimentally induced by the SPST. Repeated-measures ANOVA showed significant differences in the drug for the variable related to tremor amplitude as recorded by the accelerometer.
Acute CBD administration at a dose of 300 mg decreased anxiety in patients with PD, and there was also decreased tremor amplitude in an anxiogenic situation.
大麻二酚（CBD）是大麻的主要成分之一，具有抗焦虑特性，但尚未有研究评估CBD对帕金森病（PD）患者焦虑体征和症状的影响。本研究旨在评估急性给予300mg CBD对PD患者焦虑指标以及模拟公开演讲测试（SPST）诱发的震颤的影响。
进行了一项随机、双盲、安慰剂对照、交叉临床试验。共纳入24例PD患者，在15天的间隔内进行两次实验。服用CBD或安慰剂后，参与者接受SPST。测试期间，收集以下数据：心率、全身血压以及震颤频率和幅度。此外，应用视觉模拟情绪量表（VAMS）和公开演讲时的自我陈述量表。在考虑药物、SPST阶段以及这些变量之间的相互作用的情况下，通过重复测量方差分析（ANOVA）进行统计分析。
药物在VAMS焦虑因子方面存在统计学显著差异；CBD减轻了SPST实验诱发的焦虑。重复测量ANOVA显示，药物在与加速度计记录的震颤幅度相关的变量方面存在显著差异。
急性给予300mg CBD可降低PD患者的焦虑，并且在致焦虑情况下震颤幅度也会降低。
